December 5, 2017 10:04 AM ESTUpdated 10:34 AM

Cellectis recruits ex-Servier research chief Depil; Arena inks $224M deal on new drugs; JLABS heads to Shanghai; AstraZeneca vet takes Goldfinch helm

Brittany Meiling

→ French CAR-T developer Cellectis has recruited Stéphane Depil, the former R&D chief of Servier, to lead the company’s clinical development. Depil will serve as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cellectis recruits ex-Servier research chief Depil; Arena inks $224M deal on new drugs; JLABS heads to Shanghai; AstraZeneca vet takes Goldfinch helm

Brittany Meiling

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Cel­lec­tis re­cruits ex-Servi­er re­search chief De­pil; Are­na inks $224M deal on new drugs; JLABS heads to Shang­hai; As­traZeneca vet takes Goldfinch helm

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Cellectis recruits ex-Servier research chief Depil; Arena inks $224M deal on new drugs; JLABS heads to Shanghai; AstraZeneca vet takes Goldfinch helm